Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SBK001 injection for difficult expectoration in lower respiratory tract disease
CTR20244096Phase 2Completed
- Sponsor
- Chengdu Shibeikang Biopharmaceutical Technology
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SBK001 in pulmonary infection, sponsored by Chengdu Shibeikang Biopharmaceutical Technology. Started Dec 2024; status: completed.
02
Drugs
SBK001
03
Conditions
pulmonary infection
Beyond the preview
Go deeper on CTR20244096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244096.